Stock A203400 ABION INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Abion Inc.

Equities

A203400

KR7203400007

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-05-13 EDT 		5-day change 1st Jan Change
8,380 KRW +1.33% Intraday chart for Abion Inc. +10.41% -0.59%
2023 Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc. CI
2023 TELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 6 billion in funding from Abion Inc. CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 85,498 273,810 126,828 163,611
Enterprise Value (EV) 1 102,397 240,792 114,431 167,986
P/E ratio -8.16 x -3.89 x -6.36 x -5.53 x
Yield - - - -
Capitalization / Revenue 42.9 x 167 x 50.6 x 128 x
EV / Revenue 51.4 x 147 x 45.7 x 132 x
EV / EBITDA -9.86 x -23.7 x -4.64 x -5.49 x
EV / FCF - -104,598,799 x -6,339,874 x -14,152,701 x
FCF Yield - -0% -0% -0%
Price to Book -4.28 x 8.53 x 8.4 x 18.6 x
Nbr of stocks (in thousands) 12,409 18,754 18,845 19,408
Reference price 2 6,890 14,600 6,730 8,430
Announcement Date 22-03-11 22-03-11 23-03-21 24-03-21
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales 1 1,994 1,638 2,507 1,274
EBITDA 1 -10,386 -10,170 -24,670 -30,613
EBIT 1 -10,942 -10,672 -25,167 -31,161
Operating Margin -548.8% -651.31% -1,004.06% -2,445.37%
Earnings before Tax (EBT) 1 -10,423 -54,254 -19,925 -29,211
Net income 1 -10,476 -54,259 -19,925 -29,211
Net margin -525.41% -3,311.51% -794.94% -2,292.3%
EPS 2 -844.0 -3,753 -1,059 -1,524
Free Cash Flow - -2,302 -18,049 -11,870
FCF margin - -140.5% -720.1% -931.45%
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 22-03-11 22-03-11 23-03-21 24-03-21
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 16,899 - - 4,375
Net Cash position 1 - 33,018 12,397 -
Leverage (Debt/EBITDA) -1.627 x - - -0.1429 x
Free Cash Flow - -2,302 -18,049 -11,870
ROE (net income / shareholders' equity) - -899% -84.4% -233%
ROA (Net income/ Total Assets) - -23% -45.7% -56.6%
Assets 1 - 235,869 43,553 51,608
Book Value Per Share 2 -1,608 1,712 801.0 453.0
Cash Flow per Share 2 340.0 833.0 228.0 487.0
Capex 1 291 43.2 635 5,440
Capex / Sales 14.6% 2.63% 25.35% 426.88%
Announcement Date 22-03-11 22-03-11 23-03-21 24-03-21
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ABION INC. Stock Abion Inc.
-0.59% 133M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+5.33% 111B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.11% 105B
BIONTECH SE Stock BioNTech SE
-12.56% 22.34B
ARGENX SE Stock argenx SE
-3.70% 21.93B
GENMAB A/S Stock Genmab A/S
-6.03% 18.59B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-35.21% 18.12B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.86% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.10% 13.7B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.57% 12.45B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A203400 Stock
  4. Financials Abion Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW